The partnership boosts the enrolment of at least 5,000 patients into Biological Dynamics’s ExoLuminate Study.
Biological Dynamics has signed a multi-year agreement with the Pancreatic Cancer Early Detection (PRECEDE) Consortium to improve the surveillance of early pancreatic cancer.
Leveraging Biological Dynamics’s ExoVita Pancreas Assay, powered by the Verita platform, the partnership will focus on conducting patient surveillance for this condition.
The Verita platform is intended to target and isolate blood-based exosomal protein biomarkers, thereby supporting high-sensitivity detection of early-stage cancer.
RELATED: Clinical trial design company QuantHealth scores $15M and more digital health fundings
The partnership expedites the enrolment of a minimum of 5,000 patients into Biological Dynamics’s ExoLuminate study.
The clinical study spans multiple locations and aims to identify early pancreatic ductal adenocarcinoma in individuals at a higher risk of pancreatic cancer.
It is focused on validating the ExoVita Pancreas assay for various high-risk patients.
Biological Dynamics medical director and ExoLuminate study principal investigator Harmeet Dhani said: “In order to go from a 12.5% survival rate to a 50% survival rate within five years, the answer will lie in significantly improving surveillance and accelerating detection of pancreatic cancer at stages I or II with a blood-based assay like ExoVita Pancreas.”
Biological Dynamics is said to be the first liquid biopsy partner of PRECEDE, which is an international, multi-institutional group of experts focused on improving survival rates for patients with pancreatic cancer.
Biological Dynamics CEO and director Paul Billings said: “We’re thrilled to work with PRECEDE to advance our shared goal of increasing pancreatic cancer survival rates and to further clinically validate the Verita platform and ExoVita assay for detecting cancer earlier using a new generation of exosome-based biomarkers and technology.”
